<DOC>
	<DOC>NCT00234468</DOC>
	<brief_summary>The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or without radiotherapy or chemotherapy and radiotherapy</brief_summary>
	<brief_title>Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically Confirmed Non Small Cell Lung Cancer. Locally advanced disease previously treated with combined therapy (chemotherapy and surgery with or without radiotherapy, or chemotherapy and radiotherapy). Chemotherapy with regimens containing cisplatin or carboplatin is mandatory Response to combined therapy No previous treatment with ZD1839 or any other EGFRtargeted therapy No progressive disease after combined therapy for locally advanced NSCLC No presence of metastatic disease No other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ Any unresolved chronic toxicity from previous anticancer therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Locally Advanced Non Small Cell Lung Cancer (Stage IIIA and IIIB)</keyword>
</DOC>